Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Mills · SciRah

Researcher profile · Semantic Scholar

A. Mills

Share profile

A. Mills — researcher profile on SciRah

h-index: 34
Works: 84
Citations: 5,782

Most-cited papers

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
D. Wyles, P. Ruane, M. Sulkowski, D. Dieterich +23 more
2015New England Journal of Medicine574 citations Open access
Semantic Scholar
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
J. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich +10 more
2007The Lancet483 citations
Semantic Scholar
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
P. Sax, E. Dejesus, A. Mills, A. Zolopa +11 more
2012The Lancet456 citations
Semantic Scholar
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
J. Molina, P. Cahn, B. Grinsztejn, A. Lazzarin +8 more
2011The Lancet417 citations
Semantic Scholar
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
A. Castagna, F. Maggiolo, G. Penco, D. Wright +86 more
2014Journal of Infectious Diseases338 citations Open access
Semantic Scholar
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
J. Gallant, A. Lazzarin, A. Mills, C. Orkin +13 more
2017The Lancet314 citations Open access
Semantic Scholar
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
A. Mills, M. Nelson, Dushyantha T. Jayaweera, K. Ruxrungtham +7 more
2009AIDS (London)292 citations Open access
Semantic Scholar
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
A. Mills, J. Arribas, J. Andrade-Villanueva, G. Diperri +18 more
2016Lancet. Infectious Diseases (Print)291 citations Open access
Semantic Scholar
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
A. Mills, G. Crofoot, C. Mcdonald, P. Shalit +15 more
2015Journal of Acquired Immune Deficiency Syndromes151 citations Open access
Semantic Scholar
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
J. Molina, D. Ward, I. Brar, A. Mills +11 more
2018The Lancet HIV150 citations
Semantic Scholar
A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
A. Zolopa, P. Sax, E. Dejesus, A. Mills +9 more
2013Journal of Acquired Immune Deficiency Syndromes148 citations Open access
Semantic Scholar
ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects
S. Letendre, A. Mills, K. Tashima, Deborah A. Thomas +4 more
2014Clinical Infectious Diseases137 citations Open access
Semantic Scholar
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
J. Molina, K. Squires, P. Sax, P. Cahn +134 more
2018The Lancet HIV136 citations
Semantic Scholar
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
C. Katlama, B. Clotet, A. Mills, B. Trottier +8 more
2010Antiviral Therapy110 citations Open access
Semantic Scholar
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b
A. Pozniak, M. Markowitz, A. Mills, H. Stellbrink +9 more
2014Lancet. Infectious Diseases (Print)109 citations
Semantic Scholar
A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
D. Wohl, C. Cohen, J. Gallant, A. Mills +9 more
2014Journal of Acquired Immune Deficiency Syndromes105 citations Open access
Semantic Scholar
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
P. Sax, E. Dejesus, G. Crofoot, D. Ward +10 more
2017The Lancet HIV91 citations
Semantic Scholar
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
E. Dejesus, Bernard Haas, S. Segal-maurer, M. Ramgopal +5 more
2018AIDS Research and Human Retroviruses90 citations
Semantic Scholar
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
M. Murray, A. Antela, A. Mills, Jenny Huang +14 more
2020Aids and Behavior82 citations Open access
Semantic Scholar
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
J. Eron, C. Orkin, J. Gallant, J. Molina +10 more
2018AIDS (London)82 citations Open access
Semantic Scholar
Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens
A. Mills, C. Cohen, E. Dejesus, C. Brinson +7 more
2013HIV Clinical Trials78 citations Open access
Semantic Scholar
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
J. Nadler, D. Berger, G. Blick, P. Cimoch +18 more
2007AIDS (London)73 citations Open access
Semantic Scholar
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
C. Orkin, E. Dejesus, M. Ramgopal, G. Crofoot +17 more
2017The Lancet HIV71 citations
Semantic Scholar
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
V. Chounta, E. Overton, A. Mills, S. Swindells +9 more
2021Patient70 citations Open access
Semantic Scholar
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Devi SenGupta, C. Brinson, E. Dejesus, A. Mills +20 more
2021Science Translational Medicine69 citations
Semantic Scholar
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
K. Hardt, A. Vandebosch, J. Sadoff, Mathieu le Gars +284 more
2022Lancet. Infectious Diseases (Print)65 citations Open access
Semantic Scholar
Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies
M. R. Nelson, R. Elion, C. Cohen, A. Mills +10 more
2013HIV Clinical Trials64 citations Open access
Semantic Scholar
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults
J. Gallant, J. Brunetta, G. Crofoot, P. Benson +8 more
2016Journal of Acquired Immune Deficiency Syndromes63 citations Open access
Semantic Scholar
Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.
S. Riddler, M. Para, C. Benson, A. Mills +21 more
2020Clinical Infectious Diseases58 citations Open access
Semantic Scholar
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
D. Hagins, C. Orkin, E. Daar, A. Mills +15 more
2018HIV Medicine54 citations Open access
Semantic Scholar
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
E. Dejesus, M. Ramgopal, G. Crofoot, P. Ruane +14 more
2017The Lancet HIV46 citations
Semantic Scholar
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
Sonia Vibhakar Patel, D. Jayaweera, K. Althoff, J. Eron +9 more
2020PLoS ONE45 citations Open access
Semantic Scholar
Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study
A. Mills, D. Mildvan, D. Podzamczer, G. Fätkenheuer +10 more
2013Journal of Acquired Immune Deficiency Syndromes41 citations Open access
Semantic Scholar
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
J. Eron, S. Little, G. Crofoot, P. Cook +13 more
2024The Lancet HIV37 citations Open access
Semantic Scholar
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study
M. Murray, F. Pulido, A. Mills, M. Ramgopal +8 more
2019HIV Research & Clinical Practice33 citations Open access
Semantic Scholar
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
A. Mills, G. Richmond, C. Newman, O. Osiyemi +12 more
2021AIDS (London)30 citations Open access
Semantic Scholar
Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis
G. Behrens, B. Rijnders, M. Nelson, C. Orkin +12 more
2014AIDS Patients Care and STDs30 citations Open access
Semantic Scholar
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
S. Letendre, A. Mills, D. Hagins, S. Swindells +10 more
2019Journal of Antimicrobial Chemotherapy29 citations Open access
Semantic Scholar
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses
Eunsil Choi, Chad J. Michalski, Seungyoup Choo, G. Kim +16 more
2016Retrovirology28 citations Open access
Semantic Scholar
Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data
A. Mills, G. Crofoot, R. Ortiz, B. Rashbaum +9 more
2014HIV Clinical Trials25 citations Open access
Semantic Scholar
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment‐naïve patients
E. Dejesus, A. Mills, L. Bhatti, C. Conner +1 more
2011International journal of clinical practice22 citations Open access
Semantic Scholar
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
A. Mills, G. Rizzardini, M. Ramgopal, O. Osiyemi +12 more
2024The Lancet HIV20 citations
Semantic Scholar
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and T
A. Mills, W. Garner, A. Pozniak, J. Berenguer +3 more
2015Patient17 citations Open access
Semantic Scholar
Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males.
S. Schrader, A. Mills, Mark Scheperle, J. Block
2005Clinical Cornerstone17 citations
Semantic Scholar
Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
J. Eron, Chien-Ching Hung, J. Baril, J. Slim +15 more
2020Journal of Acquired Immune Deficiency Syndromes15 citations Open access
Semantic Scholar
Uninsured free clinic patients’ experiences and perceptions of healthcare services, community resources, and the Patient Protection and Affordable Care Act
Akiko Kamimura, Jeanie Ashby, H. Trinh, L. Prudencio +5 more
201614 citations Open access
Semantic Scholar
2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results
D. Margolis, K. Sutton, J. de Vente, R. Leblanc +8 more
2019Open Forum Infectious Diseases10 citations Open access
Semantic Scholar
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
E. Lathouwers, E. Y. Wong, K. Brown, B. Baugh +159 more
2019AIDS Research and Human Retroviruses10 citations Open access
Semantic Scholar
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients
A. Zolopa, Joel E. Gallant, C. J. Cohen, Paul E. Sax +6 more
201210 citations Open access
Semantic Scholar
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
P. Sax, E. Dejesus, G. Crofoot, D. Ward +7 more
2018AIDS (London)7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Dejesus×19
Invite
E. Dejesus — researcher profile on SciRah
A. Cheng×14
Invite
A. Cheng — researcher profile on SciRah
M. Ramgopal×12
Invite
M. Ramgopal — researcher profile on SciRah
C. Brinson×11
Invite
C. Brinson — researcher profile on SciRah

×8

Invite

P. Sax — researcher profile on SciRah

Invite

K. White — researcher profile on SciRah

Invite

J. Gallant — researcher profile on SciRah

Invite

J. Molina — researcher profile on SciRah

Invite

D. Ward — researcher profile on SciRah

Invite

C. Orkin — researcher profile on SciRah

Invite

G. Crofoot — researcher profile on SciRah

Invite

C. Cohen — researcher profile on SciRah